Brief: Candel Therapeutics Announces $100 Mln Royalty Funding Agreement With RTW
19/02/2026 21:37
Feb 19 (Reuters) - Candel Therapeutics Inc CADL.O: CANDEL THERAPEUTICS ANNOUNCES $100M ROYALTY FUNDING AGREEMENT WITH RTW TO SUPPORT THE POTENTIAL LAUNCH OF AGLATIMAGENE BESADENOVEC (CAN-2409) IN LOCALIZED PROSTATE CANCER CANDEL THERAPEUTICS: UNDER AGREEMENT, RTW WILL RECEIVE A TIERED SINGLE DIGIT PERCENTAGE OF ANNUAL NET SALES OF AGLATIMAGENE IN U.S. SUBJECT TO A CAP Source text: ID:nGNX3bbvhj Further company coverage: CADL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec